Regeneron Pharmaceuticals, Inc. and Jazz Pharmaceuticals plc: A Detailed Gross Profit Analysis

Biotech Giants: Regeneron vs. Jazz - A Decade of Growth

__timestampJazz Pharmaceuticals plcRegeneron Pharmaceuticals, Inc.
Wednesday, January 1, 201410554570002614539000
Thursday, January 1, 201512222770003711019000
Friday, January 1, 201613825870004560733000
Sunday, January 1, 201715085050005475166000
Monday, January 1, 201817693780006276700000
Tuesday, January 1, 201920338310007081200000
Wednesday, January 1, 202022146500007377200000
Friday, January 1, 2021265347800013634200000
Saturday, January 1, 2022311885700010612500000
Sunday, January 1, 2023339862700011301400000
Monday, January 1, 202412231500000
Loading chart...

Igniting the spark of knowledge

A Decade of Growth: Regeneron vs. Jazz Pharmaceuticals

In the competitive landscape of biotechnology, Regeneron Pharmaceuticals, Inc. and Jazz Pharmaceuticals plc have demonstrated remarkable growth over the past decade. From 2014 to 2023, Regeneron's gross profit surged by approximately 332%, peaking in 2021 with a staggering $13.6 billion. This growth trajectory underscores Regeneron's strategic advancements in innovative therapies and market expansion.

Conversely, Jazz Pharmaceuticals showcased a steady increase in gross profit, growing by around 222% over the same period. By 2023, Jazz's gross profit reached $3.4 billion, reflecting its successful portfolio diversification and strategic acquisitions.

This analysis highlights the dynamic nature of the pharmaceutical industry, where strategic innovation and market positioning are key to financial success. As these companies continue to evolve, stakeholders and investors should keenly observe their strategic maneuvers and market responses.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025